

# COVIDIV - Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents

Head :Mauget-Faÿsse Martine

Last update : 04/23/2021 | Version : 1 | ID : 73553

General	
Identification	
Detailed name	Collateral damage of the COVID-19 pandemic observed among patients receiving treatment with intravitreal (IVT) injections of antiangiogenic agents
Sign or acronym	COVIDIV
General Aspects	
Medical area	Ophthalmology
Study in connection with Covid-19	Yes
Pathology (details)	Exudative ARMD, diabetes, retinal vein occlusion (RVO), or other disorders causing macular oedema
Scientific investigator(s) (Contact)	
Name of the director	Mauget-Faÿsse
Surname	Martine
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 64 37
Organization	Foundation A. de Rothschild Hospital
Collaborations	
Participation in projects, networks and consortia	No
Funding	
Governance of the database	
Sponsor(s) or organisation(s)	Foundation A. de Rothschild Hospital/Clinical

responsible	Research Unit
Organisation status	Both
Presence of scientific or steering committees	No

Additional contact

Name of the contact	VACHEY
Surname	Patrick
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 64 33
Email	pvachey@for.paris
Organization	Hôpital Fondation A. de Rothschild

Name of the contact	THEVENIN
Surname	Sophie
Address	Hôpital Fondation A. de Rothschild, PIC-CIC, 29 rue Manin 75019 PARIS
Phone	01 48 03 65 96
Email	sthevenin@for.paris
Organization	Hôpital Fondation A. de Rothschild

Main features

Type of database

Type of database	Others
Specify	Questionnaire at inclusion + follow-up data taken from the medical records
Database recruitment is is made on the basis of:	Medication(s) taken

Database recruitment is carried out as part of an interventional study	No
Additional information regarding	Patient information following their first visit after the

sample selection.	first lockdown on 11/05/2021: Patients contacted by telephone or informed during appointments.
Database objective	
Main objective	Describe the changes in visual acuity among patients receiving treatment with repeat IVT injections of antiangiogenic agents during the COVID-19 epidemic, between September 2019 and May 2021
Inclusion criteria	<p>Patient aged 18 years and over</p> <p>-Eye disorder requiring treatment with repeat IVT injections of antiangiogenic agents: Exudative ARMD, macular oedema associated with diabetes or secondary to retinal vein occlusion.</p> <p>-Initiation of treatment with repeat IVT injections before 01/10/2019</p>
Population type	
Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p> <p>Great age (80 years and more)</p>
Population covered	Sick population
Pathology	H35 - Other retinal disorders
Gender	<p>Male</p> <p>Woman</p>
Geography area	National
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[ individuals
Details of the number of individuals	1,500 planned - actual number included: 233
Data	

Database activity	Current data collection
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Direct physical measures
Details of collected clinical data	Treatment with IVT injections, outcome of the treated disorder
Declarative data (detail)	Phone interview
Details of collected declarative data	Questionnaire on visits during the lockdown
Presence of a biobank	No
Procedures	
Participant monitoring	Yes
Details on monitoring of participants	Follow-up with data in the medical records up to a year after resuming follow-up after 11/05/2021
Links to administrative sources	No
Promotion and access	
Promotion	
Access	